Firebrick Pharma Limited

FRE

AU0000197352

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 01:53:36 2024-06-07 am EDT			5-day change	1st Jan Change
0.056 ^AUD	0.00%		-6.67%	+12.00%

May. 23	Firebrick Pharma Obtains Nasodine Composition Patent in South Africa	MT
May. 17	Firebrick Pharma Raises AU$800,000 via Placement	MT

Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2022

February 17, 2023 at 12:51 am EST

Firebrick Pharma Limited reported earnings results for the half year ended December 31, 2022. For the half year, the company reported sales was AUD 0.00083 million compared to AUD 0.003372 million a year ago. Net loss was AUD 3.13 million compared to AUD 1.54 million a year ago.

Basic loss per share from continuing operations was AUD 0.0185 compared to AUD 0.0129 a year ago.

Latest news about Firebrick Pharma Limited

Firebrick Pharma Obtains Nasodine Composition Patent in South Africa	May. 22	MT
Firebrick Pharma Raises AU$800,000 via Placement	May. 16	MT
Firebrick Pharma Appoints Auditor	May. 05	MT
Firebrick Pharma's Nasodine Nasal Spray Enters US Market	Apr. 16	MT
Firebrick Pharma Phase 2 Covid-19 Trial Published in Laryngoscope Journal	Apr. 03	MT
Firebrick Pharma Gets Coverage Extension of COVID-19 Patent in US	Mar. 03	MT
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
62,732,537 Ordinary Shares of Firebrick Pharma Limited are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
Firebrick Pharma to Release Shares from Escrow; Shares Rise 4%	Jan. 11	MT
Firebrick Pharma Withdraws Appeal Against Regulator's Decision Over Nasodine Nasal Spray	Dec. 27	MT
Firebrick Pharma's Nasodine Nasal Spray COVID-19 Patent Granted in South Africa	Nov. 29	MT
Firebrick Pharma Receives AU$1.8 Million R&D Tax Rebate	23-10-31	MT
Firebrick Says Independent Probe Into Nasodine Trial Results Did Not Find Errors	23-10-04	MT
Firebrick Pharma's Cold Medication Fails Phase III Trial	23-09-13	MT
Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common Cold	23-09-12	CI
Firebrick Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Firebrick Pharma Completes Enrollment for Cold Treatment Trial; Shares Soar 17%	23-08-09	MT
Firebrick Update on Administrative Appeals Tribunal Process	23-07-19	CI
Firebrick Pharma's Nasal Spray Patent Allowed in Canada	23-05-08	MT
Firebrick Pharma Raises AU$1 Million From Share Placement; Shares Slump 10%	23-04-30	MT
Firebrick Pharma Resumes Phase Three Trial for Cold Medication; Shares Jump 8%	23-03-20	MT
Firebrick Pharma Limited Announces Resume of Phase 3 Clinical Trial of Nasodine Nasal Spray	23-03-20	CI
Firebrick Pharma Files Pediatric Investigation Plan in Europe for Common Cold Treatment	23-02-21	MT
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-17	CI
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-17	CI

Chart Firebrick Pharma Limited

Duration

Period

More charts

Company Profile

Firebrick Pharma Limited is an Australia-based pharmaceutical company. The principal activity for the Company is the clinical development and partnering of Nasodine, a broad-spectrum antimicrobial spray for the treatment of the common cold. The Company has developed a povidone-iodine nasal spray, called Nasodine Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the United States, Europe and Australia. The Company has also completed six clinical trials for Nasodine, including a Phase I study, three Phase II studies and two Phase III studies, which have affirmed the productâs safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Nasodine Phase II COVID-19 trail achieves primarily endpoints.

Sector

Pharmaceuticals

Calendar

2024-08-14 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FIREBRICK PHARMA LIMITED	+12.00%	7.2M
ELI LILLY AND COMPANY	+47.67%	765B
JOHNSON & JOHNSON	-6.24%	354B
MERCK & CO., INC.	+20.48%	331B
ABBVIE INC.	+9.79%	299B
ASTRAZENECA PLC	+18.87%	248B
ROCHE HOLDING AG	-1.96%	219B
NOVARTIS AG	+11.11%	216B
AMGEN INC.	+5.15%	164B
PFIZER, INC.	-2.43%	162B